Fractyl Health (GUTS) Cash & Equivalents (2023 - 2026)

Fractyl Health (GUTS) has 4 years of Cash & Equivalents data on file, last reported at $63.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 50.04% year-over-year to $63.2 million; the trailing twelve-month figure through Mar 2026 stood at $63.2 million (up 50.04% YoY), and the FY2025 full-year result was $81.5 million, up 20.86% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $63.2 million, down from $81.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $121.4 million in Q1 2024 and bottomed at $22.3 million in Q2 2025.
• A 4-year average of $69.6 million and a median of $72.6 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 103.15% in 2024 and slumped 78.23% in 2025, its largest moves.
• Tracing GUTS's Cash & Equivalents over 4 years: stood at $33.2 million in 2023, then surged by 103.15% to $67.5 million in 2024, then climbed by 20.86% to $81.5 million in 2025, then fell by 22.53% to $63.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $63.2 million, $81.5 million, and $77.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison